 HER2 breast cancer therapies: a review

Conleth G Murphy
Shanu Modi
Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Abstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to ‘HER2 normal’ breast cancer. Research has focused on developing therapies directed to the HER2 receptor and its pathway. These include the monoclonal antibody trastuzumab, which has improved outcomes when used in patients with both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor which has demonstrated activity in advanced breast cancer and is currently being evaluated in early stage disease. We discuss the therapeutic rationale and clinical trial experience with these agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, antibody–drug conjugates, agents targeting downstream components of the HER2 signaling pathway, and heat shock protein 90 (HSP90) inhibitors.

Keywords: HER2, human epidermal growth factor receptor 2, breast cancer, trastuzumab, lapatinib

The human epidermal growth factor receptor 2 (HER2) gene, also known as c-erbB2 and neu, encodes a 185-kDa transmembrane glycoprotein receptor. This receptor belongs to the ErbB family of growth factor receptors with intrinsic tyrosine kinase activity, the members of which exist in homodimer and heterodimer form when activated. Other members of the ErbB family are the epidermal growth factor receptor 1 (EGFR/HER1), HER3 and HER4. Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer prognosis on multivariate analyses. In an effort to improve the outcomes of patients with HER2 positive (HER2+) breast cancer, research has focused on developing therapies directed to the HER2 receptor and its pathway. These therapies, which include the monoclonal antibody trastuzumab and the small molecule tyrosine kinase inhibitor lapatinib, as well as other novel and emerging strategies, will be discussed in this review. The mechanisms of action of the therapies discussed in this review are summarized in Table 1.

Trastuzumab
The initial HER2 targeting antibody was a murine monoclonal antibody targeting the extracellular domain IV of the receptor (muMAb 4D5), derived by immunizing mice with cells that expressed high levels of the HER2 protein product. In order to...
decrease the risks associated with the development of human antimouse antibodies, a humanized version (rhuMAb HER2 or trastuzumab) was engineered by inserting the antigen-binding residues of 4D5 into a cloned human immunoglobulin G (IgG) framework. The mechanisms through which trastuzumab exerts its effects in vivo are not completely understood but are likely to include antibody-dependent cellular cytotoxicity (ADCC), disruption of critical downstream proliferative signaling pathways and inhibition of cell cycle progression, and antiangiogenic effects. Some evidence suggests that downregulation of surface HER2 protein by endocytosis and degradation is a further mechanism of action of trastuzumab, although data are conflicting.

Following extensive preclinical testing, a phase II study evaluated trastuzumab single agent therapy in 46 women with pretreated HER2+ metastatic breast cancer (MBC). HER2 positivity was defined as those tumors in which at least 25% of cells exhibited characteristic membrane staining for the HER2 receptor. Based on preclinical data, trastuzumab was administered as a loading dose of 250 mg followed by 100 mg weekly for 10 weeks. The overall response rate (ORR) was 11.6% and an additional 37% of patients achieved minimal responses or stable disease. This study provided the first clinical evidence for activity with an HER2 targeted therapy in breast cancer.

Subsequent larger multicenter phase II studies delivering weekly trastuzumab monotherapy for metastatic disease have confirmed these results. Cobleigh et al treated 222 women with HER2+ pretreated MBC with trastuzumab 4 mg/kg loading dose, followed by weekly infusions of 2 mg/kg. HER2 positivity was defined in terms of the protein product by central laboratory immunohistochemistry (IHC) staining of 2+ or 3+. The overall response rate in these pretreated patients was 15%, with a duration of response of 9.1 months.

Vogel et al enrolled 114 patients with previously untreated HER2+ MBC, randomizing patients between two dose schedules of trastuzumab: a 4 mg/kg loading dose followed by 2 mg/kg weekly as in the previous study, and a higher dose schedule using 8 mg/kg as a loading dose followed by 4 mg/kg weekly. The ORR in these patients was 26% with no difference in outcomes between the two dose schedules. Notably, the response rate for tumors staining 3+ by IHC was 35%, with no responses seen in the group staining 2+. Retrospective HER2 gene amplification analysis by fluorescence in situ hybridization (FISH) was performed on a subset of women in this study: response rates of 34% were seen in the FISH-positive women compared with 7% in the FISH-negative women.

### Pivotal trastuzumab trials for metastatic disease

The landmark phase III trial which led to the approval of trastuzumab for metastatic disease in combination with chemotherapy, enrolled 469 women with HER2+ MBC who were randomized to standard first-line chemotherapy or chemotherapy plus trastuzumab. HER2 positivity was defined

---

#### Table 1 Mechanisms of action of agents discussed

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug type</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trastuzumab</td>
<td>Monoclonal antibody against HER2 extracellular domain IV</td>
<td>Antibody-dependent cell-mediated cytotoxicity(^{9})</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disrupts downstream proliferative signaling pathways(^{9})</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inhibits cell cycle progression(^{9})</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antiangiogenic effects(^{10})</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endocytosis and degradation of HER2(^{21})</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Small molecule tyrosine kinase inhibitor of EGFR and HER2</td>
<td>Inhibits receptors’ intrinsic tyrosine kinase activity(^{48})</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prevents downstream transmission of activation signal(^{42})</td>
</tr>
<tr>
<td>Tanespimycin</td>
<td>Heat shock protein 90 (HSP90) inhibitor</td>
<td>Inhibits HSP90’s stabilizing effect on client proteins(^{73–75})</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Facilitates HER2 degradation(^{76–77})</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>Monoclonal antibody against HER2 extracellular domain II</td>
<td>Antibody dependent cell-mediated cytotoxicity(^{99})</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prevents HER2 heterodimerization(^{97})</td>
</tr>
<tr>
<td>Trastuzumab-MCC-DM1</td>
<td>Antibody drug conjugate linking trastuzumab to microtubule cytotoxic</td>
<td>Targeted cytotoxic drug delivery(^{90})</td>
</tr>
<tr>
<td>Neratinib</td>
<td>Irreversible pan-erbB tyrosine kinase inhibitor</td>
<td>Irreversibly inhibits tyrosine kinase activity of HER1, HER2 and HER4(^{49})</td>
</tr>
<tr>
<td>Everolimus</td>
<td>Small molecule serine-threonine kinase inhibitor of mTOR</td>
<td>Inhibits proliferative signaling pathway downstream of HER2(^{26})</td>
</tr>
</tbody>
</table>
by IHC staining of 2+ or 3+, rather than by gene amplification. Standard chemotherapy consisted of an anthracycline (doxorubicin or epirubicin) plus cyclophosphamide for those patients who had not been exposed to anthracyclines in the adjuvant setting, or paclitaxel for those who had previously received anthracyclines. Additionally, patients receiving chemotherapy alone could cross over to receive trastuzumab at the time of progression. Chemotherapy was administered every 3 weeks for 6 cycles (with an option of continuing at the investigator’s discretion) and trastuzumab was given weekly until progression of disease. The primary endpoint of the trial was time to progression (TTP), and this was prolonged from 4.6 to 7.4 months with the addition of trastuzumab to chemotherapy ($P < 0.001$); there was also an improvement in the objective response rate from 32% to 50% ($P < 0.001$), the median duration of response from 6.1 to 9.1 months ($P < 0.001$) and a prolongation of median overall survival (OS) from 20.3 versus 25.1 months ($P = 0.046$) in favor of the trastuzumab arm. These clinical outcomes are particularly striking given that 2/3 of the patients in the control arm crossed over to receive trastuzumab at the time of progression. These were the pivotal data that led to the approval of trastuzumab as first-line treatment of HER2+ MBC. A second randomized trial of docetaxel chemotherapy ± trastuzumab for a comparable cohort of patients produced similar results.\(^{17}\)

A number of phase II studies have evaluated the addition of trastuzumab to different chemotherapy agents including docetaxel,\(^{18}\) paclitaxel,\(^{19}\) vinorelbine,\(^{20}\) capecitabine,\(^{21}-^{23}\) platinum agents\(^{24,25}\) and gemcitabine\(^{26}\) with ORR ranging from 20% to 68% and acceptable toxicity profiles. The definition of HER2 positivity varied for these trials, with some using IHC staining of 2+/3+ as eligibility criteria, and others stipulating IHC staining of 3+ and/or FISH positivity. Overall, these combinations represent viable salvage treatment options for patients with advanced stage HER2+ MBC.

**Trastuzumab beyond progression?**

A critical issue regarding the continued use of trastuzumab in the face of disease progression has only recently been addressed by prospective randomized data. Von Minnervitz and colleagues conducted a phase III trial of capecitabine vs capecitabine plus trastuzumab in patients with HER2+ MBC progressing on trastuzumab-containing therapy.\(^{27}\) Although accrual to this trial was halted early on the advice of an independent data monitoring committee with only 156 of a planned 482 patients enrolled, there was a significant improvement in progression-free survival (PFS) from 5.6 months to 8.2 months in the trastuzumab arm at a median follow-up of 15.6 months ($P = 0.03$).

These were the first randomized data to show a benefit for the continuation of trastuzumab in spite of disease progression, lending credence to an approach that was previously widely adopted in common practice for the treatment of patients with HER2+ disease.

**Adjuvant trastuzumab trials**

The improvement in outcomes resulting from the addition of trastuzumab to chemotherapy in the metastatic setting led to its investigation as an adjunct to chemotherapy in the adjuvant arena. Four large multicenter randomized trials accrued thousands of patients, and reported interim outcome analyses in 2005: NSABP B-31, NCCTG N9831, HERA and BCIRG 006.\(^{28-30}\) In addition, two smaller studies designed to compare different chemotherapy regimens incorporated a randomization to trastuzumab for HER2+ patients, and reported outcomes in subsequent years: FinHER and PACS 04.\(^{31,32}\) The study designs of these trials are summarized in Figure 1.

In the B-31 and N9831 trials, patients with early stage HER2+ breast cancer were all treated with a standard North American adjuvant chemotherapy regimen of 4 cycles of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T); half of these patients were randomized to additionally receive trastuzumab therapy for 1 year. Because of similarities in the design and patient populations of the two studies, a joint analysis of the data was undertaken, with the primary endpoint of evaluating disease-free survival (DFS).\(^{29}\) In both trials trastuzumab was initiated with the taxane component of chemotherapy in the investigational arm (a third arm of the N9831 study deferred trastuzumab until after the taxane). A combined total of 1833 patients were randomized to trastuzumab, with a control population of 1843 patients. Lymph-node positive patients only were enrolled, apart from 191 ‘high-risk’ node-negative patients who were accrued to N9831 after a protocol amendment in May 2003. At a median follow-up of 2 years (2.4 years for B-31 and 1.5 years for N9831) there was a significant improvement in DFS for patients receiving trastuzumab, with a hazard ratio (HR) for first events of 0.48 (95% CI 0.39–0.59; $P < 0.0001$). In addition, there was a 33% reduction in the risk of death in this group (HR 0.67, 95% CI 0.48-0.93; $P = 0.015$).

Simultaneously, a European multi-center trial (HERA) was evaluating the use of trastuzumab after chemotherapy in over 5000 HER2+ patients.\(^{28}\) While the majority of patients in this study were also node-positive, approximately one third of the patients had node-negative tumors measuring at least 1 cm.
The investigators randomized patients to either 1 or 2 years of trastuzumab versus observation after chemotherapy. A single chemotherapy regimen was not selected, but patients must have received a minimum of 4 cycles of predefined adjuvant and/or neoadjuvant therapy. The first interim analysis after only 1 year of median follow-up demonstrated a statistical improvement in DFS among patients receiving 1 year of trastuzumab compared with observation, with a HR of 0.54 (95% CI 0.43–0.67; \( P \leq 0.0001 \)). At the second interim analysis with a median follow-up of 23.5 months, there was a statistically significant 34% reduction in the risk of death (HR 0.66, 95% CI 0.47–0.91; \( P = 0.0115 \)).

Efficacy results for the 2-year trastuzumab arm are keenly awaited and are expected in 2009.

The BCIRG 006 study randomized 3222 HER2+ patients to 3 arms: doxorubicin and cyclophosphamide (AC) for 4 cycles followed by docetaxel for 4 cycles; AC for 4 cycles followed by docetaxel for 4 cycles plus trastuzumab for 1 year; and a third novel arm lacking an anthracycline, of docetaxel plus carboplatin and trastuzumab, with trastuzumab continuing for 1 year. Based on preclinical data suggesting a synergistic effect of trastuzumab with platinum compounds, this study incorporated this third arm without anthracyclines to try and minimize cardiac risk. At an interim analysis performed at 36 months of follow-up, the results demonstrated a significant improvement in DFS and OS for both trastuzumab containing arms compared to chemotherapy alone. The HR for DFS in the anthracycline-containing trastuzumab and nonanthracycline arms compared to the control arm were 0.61 and 0.67, respectively; for OS, the HRs were 0.59 and 0.66, respectively. All results were statistically significant. Most importantly, the incidence of grade 3/4 cardiac toxicity with the novel nonanthracycline arm was similar to the control arm (0.4% vs 0.3%) and less than that of the anthracycline plus trastuzumab arm (2%). This was the fourth trial to confirm a significant reduction in the risk of recurrence with the addition of trastuzumab to chemotherapy for HER2+ early stage breast cancer, with the additional advantage of a minimally cardiotoxic chemotherapy regimen.

FinHER was a small study in which HER2+ patients (232 in total) were randomized to a notably shorter duration of
trastuzumab therapy (9 weekly doses) in combination with either docetaxel or vinorelbine or to these chemotherapy agents alone. All patients then proceeded to 3 cycles of anthracycline-containing chemotherapy. This study was powered to detect a 50% to 67% improvement in recurrence-free survival in the HER2+ patients treated with trastuzumab, at a power of 0.80. In spite of this threshold, the study achieved this aim with a HR for recurrence of 0.42 (95% CI 0.21–0.83; \( P = 0.01 \)) and a HR for death of 0.41 (95% CI 0.16–1.08; \( P = 0.07 \)). Although the study was small, it achieved similar levels of risk reduction as seen with 1 year of adjuvant trastuzumab, and raised the question of duration for the antibody in this setting. While currently 1 year of adjuvant trastuzumab remains the standard of care for HER2+ early breast cancer, results from the 2-year arm of the HERA trial and the ongoing Greek and French studies randomizing patients to 6 vs 12 months of trastuzumab in the adjuvant setting may help define the optimal duration of treatment.

The lone trial that has not shown an advantage for trastuzumab in the adjuvant setting is the PACS 04 trial in which 528 HER2+ patients were randomized to 1 year of trastuzumab or observation after completion of adjuvant chemotherapy. Although there was a trend for benefit in the first 18 months, in the intent-to-treat analysis after a median follow-up of 48 months, there was no significant difference observed in either the DFS or OS between the trastuzumab and the observation arms. The small study size, statistical power, and sequential versus concurrent administration of the trastuzumab in this trial have been raised as possible explanations for this negative result; additional studies and further followup of the 4 large randomized trials and other ongoing studies may help to place these provocative data in context.

Trastuzumab toxicity

It was not immediately apparent from the early clinical trials with trastuzumab that cardiac toxicity would be a major concern with this agent. Rates of cardiac dysfunction in the two major studies of trastuzumab monotherapy (as defined by congestive heart failure, cardiomyopathy or left ventricular ejection fraction (LVEF) decline >10% points) were relatively modest at 2% to 4.7%. However, in the landmark phase III trial with chemotherapy, the use of trastuzumab concurrently with anthracyclines appeared to dramatically increase the rate of cardiac dysfunction, from 8% in the anthracycline chemotherapy group to 27% in the anthracycline and trastuzumab group. Accordingly, concurrent use of anthracyclines and trastuzumab is not advised, apart from the neoadjuvant setting where there is limited experience demonstrating safety and efficacy for concurrent administration.

Given the potential for cardiac dysfunction, there was rigorous cardiac monitoring as part of the adjuvant trastuzumab trials which has allowed for prospective monitoring and evaluation of this toxicity. After 5 years of follow-up, there was a 4% incidence of class III/IV congestive heart failure (CHF) or cardiac death in the patients receiving trastuzumab on the adjuvant B31 trial. A detailed cardiac safety analysis of this trial revealed that trastuzumab was discontinued for asymptomatic decreases in LVEF in 14% of evaluable patients. Of those who had a repeat LVEF assessment at 6 months after discontinuation, only 25% had an LVEF value persistently below 50%. Similarly, in BCIRG 006 17.3% of patients receiving AC-TH sustained a >10% decline in LVEF relative to baseline, with 26% of patients who had repeat assessments after 42 days demonstrating persistent declines. Hence, the majority of patients will experience improved cardiac function with or without appropriate medications for CHF, suggesting a reversibility to the cardiac dysfunction induced by trastuzumab and distinguishing it from the damage imposed by anthracyclines which is largely irreversible.

And while the underlying mechanism of trastuzumab-induced cardiotoxicity is not well understood, animal studies have suggested an important role for HER2 signaling pathways in embryonic heart development, and in the prevention of dilated cardiomyopathy. Thus signaling through the HER2 pathway may be important for cardiac myocyte survival during periods of stress. In the absence of preventative measures, cardiac monitoring is imperative for patients on trastuzumab, particularly in the adjuvant setting where left ventricular function must be monitored every 3 to 4 months.

Beyond cardiac toxicity, trastuzumab is rarely associated with typical chemotherapy-type side effects. The most common noncardiac toxicity is infusion reactions, which were seen in 25% of patients during the first infusion in the landmark study in combination with chemotherapy, and generally did not recur on subsequent infusions. Grade 3 and 4 infusion reactions were not seen in the adjuvant trastuzumab studies, perhaps due to careful pre-medication and monitoring of patients. A rare but notable toxicity encountered in the NSABP B31 and NCCTG N9831 studies was interstitial pneumonitis, which was fatal in 1 patient in each study. Additional adverse events encountered with trastuzumab alone or with chemotherapy in clinical trials for early and advanced breast cancer include arthralgia, myalgia, fatigue, dyspnea, nail...
changes, rash, headache, insomnia, thrombosis/embolism, and diarrhea, with grades 3 and 4 of any of these toxicities occurring in under 1% of patients receiving trastuzumab after adjuvant chemotherapy in the HERA study. The incidence of grade 4–5 neutropenia was increased from 0.7% to 2% when trastuzumab was added to chemotherapy in the NCCTG N9831 adjuvant study, and grade 3–5 infections/febrile neutropenia were increased from 1.4% to 3.3%. Anemia is also seen with trastuzumab, with <1% of patients receiving trastuzumab as a single agent for MBC experiencing grade 3 anemia. Rare cases of glomerulopathy causing nephrotic syndrome have also been reported in the postmarketing setting.

Trastuzumab: mechanisms of resistance

In spite of its success in the treatment of both early and advanced stage HER2+ breast cancer, a proportion of patients who receive trastuzumab-containing adjuvant therapy will relapse and nearly all patients receiving trastuzumab for metastatic disease will experience progression. A number of potential mechanisms underlying trastuzumab resistance have been proposed and include inhibition of the interaction of trastuzumab with its target protein by increased expression of the membrane glycoprotein MUC4 or shedding of the extracellular domain of the receptor leaving behind the truncated form of the receptor (p95) which retains kinase activity but cannot bind to trastuzumab. In an analysis of 46 patients with HER2+ MBC, p95 expression in the tumors was associated with clinical trastuzumab resistance. Cross talk or heterodimerization between HER2 and IGF-1R or HER family members may be another potential mechanism of resistance to trastuzumab. In these cases, signaling through other growth factor receptors may lead to the same downstream activation of the PI3K pathway resulting in cell proliferation. Looking at the pathway itself, activating mutations AKT and PIK3CA were increased from 1.4% to 3.3%. Some of these mutations can activate the PI3K pathway, resulting in cell proliferation.

The first of this new generation of HER2 targeting drugs, lapatinib (Tykerb®/Tyverb®), was approved for the treatment of HER2+ MBC by the US Food and Drug Administration (FDA) in 2007. Lapatinib, previously known as GW572016, is a reversible small-molecule tyrosine kinase inhibitor which targets both HER2 and EGFR tyrosine kinases and has the advantage of being administered orally. In vitro studies demonstrated superior growth-inhibitory effects for this molecule in HER2 and EGFR overexpressing cell lines. Additionally, lapatinib can inhibit the growth of HER2+ human breast cancer cells that are resistant to the effects of trastuzumab, as well as enhance the activity of anti-HER2 antibodies when used together. Activity in vivo was confirmed in HER2+ human breast carcinoma xenografts in mice. Inhibition of activation of downstream signaling molecules was also demonstrated in human tumor xenograft models.

Lapatinib trials

The first human studies of lapatinib were two phase I pharmacokinetic studies testing low doses of the drug in healthy subjects. Peak serum concentrations were detected at a median of 3 hours after the dose, with steady state concentrations being achieved at 6 to 7 days. The most common toxicities encountered in these healthy volunteers were headache, diarrhea, rash, cold symptoms, gastrointestinal symptoms and elevation of liver enzymes. A subsequent phase I study evaluated the safety of lapatinib in 64 patients with solid tumors (including 4 with breast cancer). Thirty-nine patients received doses of 500 mg, 750 mg or 900 mg twice daily. Twenty-five patients received doses of 900 mg bid, requiring dose reductions. A complete tumor remission was seen in 1 patient with EGFR overexpressing squamous cell carcinoma of the head and neck; in addition 22 patients experienced stable disease with a median duration of 4 months. All of the patients who continued therapy beyond 4 months were on daily doses of at least 1200 mg. The authors concluded that daily lapatinib dosing was well tolerated with evidence of clinical activity. Another phase I study evaluated 5 once daily dose cohorts in a more selected population of 67 patients with EGFR and/or HER2 overexpressing metastatic cancers. Daily doses ranged from 500 mg to 1600 mg. Lapatinib was generally well tolerated, with the most common toxicities being diarrhea in
42% and rash in 31%. The incidence of diarrhea was found to be increased with increasing dose. There were 4 partial responses (PRs), all of which were documented in patients with trastuzumab-resistant MBC (including 2 patients with inflammatory breast cancer).

A number of phase II studies followed, evaluating lapatinib monotherapy in HER2+ patients with advanced breast cancer. In the first of these, 140 patients with HER2-overexpressing and 89 with HER2 negative advanced breast cancer were treated with lapatinib 1500 mg daily. This was a heavily pre-treated population, 76% of patients having received 4 or more lines of prior chemotherapy. There were no responses seen in the HER2− cohort. The HER2+ cohort appeared to derive a slight benefit, however, with an ORR of 4.3% as determined by the investigators, and 1.4% as determined by the independent review committee. In a phase II study of HER2+ patients only, 78 patients who had progressed on prior trastuzumab therapy were randomly allocated to lapatinib as a single agent at 1250 mg or 1500 mg daily. The ORR was again relatively low in this study, at 7.7% by investigator interpretation and 5.1% as per the independent review committee. The time to progression was 15.3 weeks.

The EGF20009 study evaluated lapatinib monotherapy in a first-line setting. 138 patients who were previously untreated in the metastatic setting were randomized to 1500 mg orally daily or 500 mg twice daily. All patients were required to be HER2+ by FISH analysis; HER2 protein expression was not evaluated. No patients had received prior trastuzumab. Results were more impressive in this cohort of patients, with an ORR of 24%. By indirect comparison this result compares favorably with the ORR of 34% in the subgroup of women with HER2 FISH-amplified MBC treated in a phase II study of upfront trastuzumab monotherapy. The PFS rate at 4 months in the lapatinib study was 63%, and 43% at 6 months. There were no significant differences in outcomes between the two dosing groups. The common toxicities reported by investigators to be lapatinib-related were diarrhea (36%), rash (27%), pruritus (18%) and nausea (10%).

**Randomized lapatinib trials**

Two large randomized phase III studies investigated the addition of lapatinib to chemotherapy regimens for advanced breast cancer. EGF100151 was an open-label study which added lapatinib to chemotherapy regimens for advanced breast cancer. EGF100151 was an open-label study which added lapatinib to chemotherapy regimens for advanced breast cancer. The EGF20009 study evaluated lapatinib monotherapy in a first-line setting. In the first of these, 140 patients with HER2-overexpressing and 89 with HER2 negative advanced breast cancer were treated with lapatinib 1500 mg daily. This was a heavily pre-treated population, 76% of patients having received 4 or more lines of prior chemotherapy. There were no responses seen in the HER2− cohort. The HER2+ cohort appeared to derive a slight benefit, however, with an ORR of 4.3% as determined by the investigators, and 1.4% as determined by the independent review committee. In a phase II study of HER2+ patients only, 78 patients who had progressed on prior trastuzumab therapy were randomly allocated to lapatinib as a single agent at 1250 mg or 1500 mg daily. The ORR was again relatively low in this study, at 7.7% by investigator interpretation and 5.1% as per the independent review committee. The time to progression was 15.3 weeks.

The other phase III study of lapatinib in combination with chemotherapy (EGF30001) was a randomized, placebo-controlled study that examined the impact of adding lapatinib to paclitaxel as first-line therapy of advanced breast cancer. In contrast to the capecitabine study, HER2 negative and HER2 uncharacterized patients were enrolled onto this study. No patients had known HER2+ disease at study entry, although it was expected that a proportion would turn out to be HER2+ on testing. The paclitaxel dose was 175 mg/m$^2$ by intravenous infusion every 3 weeks, and patients were randomized to either lapatinib 1500 mg or placebo daily. In the intent-to-treat population of 579 patients, the response rate was higher for the combination arm (35% vs 25%, odds ratio = 1.7; 95% CI, 1.1–2.4; $P = 0.008$); however there were no significant difference in TTP, event-free survival (EFS) or OS. 86 patients on this study were found to have HER2+ MBC and the addition of lapatinib for this group was associated...
with a longer median TTP of 36.4 vs 25.1 weeks, with a HR for progression of 0.53 (95% CI, 0.31–0.89, \( P = 0.005 \)). EFS, ORR and clinical benefit rate (CBR) were also significantly better with combined therapy in the HER2+ subpopulation. Conversely, there was no advantage in any of the efficacy endpoints in the HER2 negative patients. The addition of lapatinib to paclitaxel was associated with significantly higher rates of rash, diarrhea, mucositis and vomiting. Furthermore, there was an increased rate of fatal adverse events in the paclitaxel/lapatinib group (8 patients, 2.7%) compared to the paclitaxel/placebo group (2 patients, 0.6%). The fatal adverse events in the lapatinib group included three cases of sepsis associated with diarrhea, mostly occurring early in the course of the trial before the investigators instituted aggressive measures to proactively manage diarrhea. The results of this study showed that HER2 negative unknown patients do not benefit from the addition of lapatinib to paclitaxel.

Lapatinib has also been combined with endocrine therapy for MBC, based on the pre-clinical evidence for cross-talk between growth factor receptor (such as HER2 and EGFR) and hormone receptor pathways as a potential mechanism for endocrine resistance.\(^6\) Results of the EGF30008 study were presented at the San Antonio Breast Cancer Symposium in December 2008.\(^6\) This study randomized 1208 patients with MBC to letrozole 2.5 mg daily with either lapatinib 1500 mg daily or placebo. Of the 219 patients in this study who had HER2+ disease, the addition of lapatinib to letrozole improved PFS from 3.0 months to 8.2 months (HR = 0.71; 95% CI, 0.53–0.96, stratified log-rank \( P = 0.019 \)) and response rates (from 28.7% to 47.7%). No effect on PFS or response rate was seen in the HER2 negative patients although an exploratory Cox regression analysis suggested a PFS benefit for lapatinib, in patients with recent tamoxifen treatment (representing endocrine resistance) as an important covariate. The combination treatment was well tolerated, with no unexpected toxicities and a low rate of asymptomatic LVEF decline (2%). A similar result was observed in the TaNDEM trial which randomized 208 patients with HER2+ MBC to first-line therapy with anastrozole + trastuzumab.\(^6\) Outcomes were superior with the combination arm in terms of PFS (4.8 vs 2.4 months, \( P = 0.0016 \)), ORR (20.3% vs 6.8 %, \( P = 0.018 \)), and CBR (42.7% vs 27.9%, \( P = 0.026 \)). Although there was a trend in OS favoring the combination arm, it was not statistically significant (28.5 vs 23.9 months, \( P = 0.325 \)). About 70% of the patients in the anastrozole only group crossed over to receive trastuzumab upon progression of disease, and the OS was the same in this group as in those who received the upfront combination.

O’Shaughnessy et al have reported results from a randomized trial of lapatinib alone versus lapatinib plus trastuzumab in patients with HER2+ MBC who progressed on trastuzumab.\(^6\) Patients were treated with either lapatinib at 1500 mg daily or lapatinib at 1000 mg daily plus weekly conventional trastuzumab. If patients progressed on the lapatinib monotherapy arm, they could cross over to the lapatinib plus trastuzumab regimen. 296 pts were randomized and results revealed a progression free survival advantage in favor of the combination of 12 weeks versus 8.4 weeks \( (P = 0.029) \) and an improvement in the clinical benefit rate of 25.2 vs 13.2 weeks \( (P = 0.02) \); response rate and overall survival were similar in both arms. Both treatment regimens were generally well tolerated. The improved clinical outcome achieved with the combination of lapatinib and trastuzumab in patients progressing on trastuzumab-based therapy further confirms the role for continued trastuzumab in spite of progression and additionally supports a role for dual modality HER2 inhibition.

### Lapatinib in CNS disease

Given its large molecular size, trastuzumab is unable to cross the blood–brain barrier (BBB) effectively. This is of particular concern, given the frequency of CNS metastases in HER2+ MBC. In a report by Bendell et al 34% of patients with HER2+ MBC developed CNS metastases at a median of 6 months from the initiation of trastuzumab therapy for metastatic disease, with 50% of these patients having stable or responding disease outside the CNS at the time.\(^6\) Furthermore, half of the patients with CNS metastases died as a result of progressive CNS disease, rather than systemic disease. Conversely, lapatinib has been shown to reduce the formation of large brain metastases in a mouse xenograft model using a trastuzumab-resistant HER2+ MBC line.\(^7\)

A phase II study of lapatinib monotherapy in 241 patients with progressive brain metastases after trastuzumab and radiotherapy demonstrated a disappointing response rate of 2.6%,\(^7\) however the authors noted that 18% of patients were progression-free at 16 weeks, and reported some favorable volumetric changes in CNS disease based on exploratory analysis. Further prospective evaluation of the role of lapatinib in the prevention of CNS disease will be explored in the adjuvant studies of lapatinib that are currently underway.

### Adjuvant lapatinib trials

The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study is an ongoing, four arm randomized study evaluating lapatinib (arm A), trastuzumab (arm B),
trastuzumab followed by lapatinib (arm C), or concurrent treatment with both agents (arm D) for early stage HER2+ breast cancer. Two trial designs are available: In design 1, patients will be randomized to one of the four anti-HER2 treatment strategies described above after completing adjuvant anthracycline-containing chemotherapy; in design 2, the anti-HER2 therapy will commence concurrently with paclitaxel, after surgery and anthracycline-based chemotherapy. A sister trial, neo-ALTTO, will test the anti-HER2 regimens in the neoadjuvant setting. An unexpected toxicity of grade 3 diarrhea seen with the concurrent paclitaxel/trastuzumab/ lapatinib combination was observed in a pilot study of this combination following dose-dense AC, where lapatinib was given at a dose of 1000 mg daily. This combination was not feasible with 34% of patients requiring a lapatinib dose reduction, predominantly due to grade 3 diarrhea. These findings led to a modification of the lapatinib dose on the corresponding arm of ALTTO trial (design 2, arm D).

Other HER2 therapies

HSP90 inhibitors

Heat shock protein 90 (HSP90) is a molecular chaperone which plays an important role in the maturation and conformational stabilization of a number of cellular ‘client’ proteins. When HSP90 is inhibited its clients are rendered unstable and ultimately they undergo degradation in the proteasome. One of the most sensitive client proteins of Hsp90 inhibition is HER2.

Tanespimycin (17AAG, 17-allylamino-17-demethoxygeldanamycin), a geldanamycin derivative, is the lead Hsp90 inhibitor in clinical development and inhibits Hsp90 function in tumors in a variety of murine models, and it has now been extensively studied as a single agent in patients with solid tumors in early phase clinical trials. A phase I study of the combination of tanespimycin and trastuzumab enrolled 25 patients with advanced solid tumors, with 15 of these patients having HER2+ MBC. Tanespimycin was administered on a weekly schedule in escalating dose cohorts in combination with weekly conventional trastuzumab. The recommended phase 2 dose for tanespimycin was determined to be 450 mg/m² weekly. The most commonly encountered toxicities were grade 1–2 vomiting, diarrhea, headache, fatigue and anorexia. Of note, no significant cardiotoxicity was encountered. Tumor regressions were observed in 5 patients, all of whom had HER2+ MBC previously progressing on trastuzumab. These results led to a phase 2 study of this combination in patients with HER2+ MBC progressing on one line of trastuzumab-based therapy.

When interim data from this study was presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2008, a total of 31 patients had been enrolled, with 27 of these evaluable for response. There were 7 patients with RECIST-defined partial responses (one unconfirmed) and an additional 5 patients with objective tumor regression measuring between 20% to 29% reduction in tumor burden; 5 patients also had disease stabilization for >4 months. The overall response rate was 26% with a clinical benefit rate of 63%. Based on these clinical results, the combination of tanespimycin plus trastuzumab is highly active for trastuzumab-treated HER2+ MBC. A number of other HSP90 inhibitor compounds are also undergoing clinical evaluation for HER2+ MBC.

Other HER2 antibodies

Pertuzumab (Omnitarg®; Genentech) is a humanized monoclonal antibody that binds to the extracellular domain II of the HER2 receptor, preventing receptor dimerization and ligand-activated signaling with other growth factor receptors, including other HER family members. In a phase II study of pertuzumab plus trastuzumab, 66 patients with HER2+ MBC progressing on trastuzumab were enrolled and treated with 3-weekly pertuzumab and weekly or 3-weekly trastuzumab. Interim results presented at the ASCO 2008 meeting revealed a RR of 24.2%, with a CBR of 50%. The most frequently encountered toxicities were grade 1 and 2 diarrhea (64%), fatigue (33%), nausea (27%), rash (26%) and headache (20%). Only 3 patients had an LVEF which declined by more than 10% from baseline to a level less than 50%. Currently a double-blind multicenter phase III study, CLEOPATRA, is randomizing patients to docetaxel plus trastuzumab versus docetaxel plus trastuzumab and pertuzumab as first-line treatment for HER2+ advanced breast cancer.

Antibody–drug conjugates

A promising strategy involves coupling targeted antibodies with potent antitumor agents, in the form of antibody–drug conjugates (ADC). Trastuzumab-MCC-DM1 (T-DM1) is an ADC using a stable thioether linkage to couple trastuzumab to a derivative of maytansine, a chemotherapeutic agent with a microtubule-binding effect similar to vinca alkaloids. T-DM1 has antitumor activity in trastuzumab-sensitive and trastuzumab-resistant preclinical models of HER2+ breast cancer. A phase I study evaluated 3-weekly dosing of T-DM1 in patients with HER2+ MBC progressing on trastuzumab. Tumor responses were seen in 5 of 9 patients (4 confirmed, 44%) at the maximally tolerated dose (MTD) of 3.6 mg/kg.
A rapidly reversible thrombocytopenia (which was grade 4 in two patients) was the dose-limiting toxicity. There was no evidence of deleterious cardiac effects. Subsequently a weekly dosing schedule achieved an MTD of 2.4 mg/kg.[93] For this schedule, 9 of 15 evaluable patients had confirmed PRs (53%). Interim results of a phase II study of 3-weekly T-DM1 as third-line therapy for patients with HER2+ MBC progressing on prior trastuzumab, were presented in 2008.[94] 107 of 122 enrolled patients were evaluable for efficacy, with a median follow-up of 4.4 months. 55% of patients had received prior lapatinib. There was no grade 3 or 4 cardiac dysfunction reported. The confirmed response rate in evaluable patients was 27.1%, and in lapatinib pretreated patients was 21.7%. Further phase II studies are now underway, including a randomized comparison of T-DM1 versus the combination of trastuzumab and docetaxel as first-line therapy for HER2+ MBC[3] and a randomized phase III trial of T-DM1 versus capecitabine plus lapatinib.[32]

Other small-molecule inhibitors of HER2 signaling

Neratinib is a low-molecular-weight pan-erbB tyrosine kinase inhibitor. In contrast to lapatinib, it irreversibly inhibits erbB1 and erbB2. It has been evaluated in trastuzumab pretreated and trastuzumab-naive patients in a phase II clinical trial.[95] A daily dose of 240 mg orally was used based on a dose-limiting toxicity of diarrhea encountered in the phase I setting. All patients had HER2 status centrally confirmed by FISH testing. The ORR was 26% for patients who had received prior trastuzumab, with a median PFS of 23 weeks. The trastuzumab-naive patients had an ORR of 56%, with a median PFS of 40 weeks. The major toxicity encountered was diarrhea, occurring in 97% of patients who had received prior trastuzumab, with a grade 3 or 4 rate of 30% in this group (13% in the trastuzumab naive patients). This agent is now undergoing evaluation in a phase III randomized trial.

mTOR inhibitors

Loss of expression of the tumor suppressor PTEN and/or activation of the PI3K/AKT signalling proteins have been reported as possible mechanisms of resistance to trastuzumab.[96] Mammalian target of rapamycin (mTOR) is a serine-threonine kinase which is a downstream component of the PTEN/PI3K pathway. Everolimus (RAD001) is an oral inhibitor of mTOR which has been evaluated with combinations of trastuzumab and various chemotherapy agents in phase I studies. Two studies reported updated analyses at SABCS 2008. Everolimus on a daily or weekly schedule was combined with weekly trastuzumab and either weekly paclitaxel[97] or vinorelbine.[98] Both studies enrolled patients with HER2+ MBC progressing on or after trastuzumab. The most common dose-limiting toxicities were neutropenia and stomatitis. Nine partial responses were seen among 27 evaluable patients with paclitaxel (41%), and 6 responses among 37 patients with vinorelbine (18%). Phase II studies are awaited.

Conclusion

Clinical studies have confirmed that trastuzumab significantly enhances the outcomes for subsets of patients with both early and late stage HER2+ breast cancer. Moreover, the HER2 receptor remains a viable target in spite of progression and is a relevant target for novel anti-HER2 strategies. Lapatinib is approved as the next line of HER2 therapy after progression on trastuzumab and other promising agents in clinical development include antibody conjugates and heat shock protein 90 inhibitors among others. Understanding the mechanisms and biochemistry of disease development and progression and targeting the specific pathways and critical proteins to the process will allow us to build on our current anticancer strategies. Trastuzumab has rightly been considered a landmark; perhaps someday it will be looked on as the first stepping stone across a wide stream.

Disclosures

The authors disclose no conflicts of interest.

References


